Thank you for the opportunity to put forward recommendations.
We've been very clear about the opportunity presented through the life sciences fund and the defence industrial strategy. There is $84 billion, if I'm recalling correctly, and we could utilize those dollars to implement a lot of the things in the recommendations that we're talking about.
We would like to designate insulin, glucagon and other essential diabetes therapies as critical medicines under a formal pharmaceutical sovereignty framework aligned with that strategy and that fund. Leverage the life sciences fund to provide capital investment for domestic insulin manufacturing. Establish public-private partnerships, with government providing strategic investment and guaranteed procurement, which is the same model that already works in defence and in critical minerals. Expand domestic fill-finish and active pharmaceutical ingredient capacity through targeted funding and regulatory support.
We would also like to see the creation of strategic reserves for essential diabetes medicines to buffer against supply disruptions and act as safeguards to protect Canadian supply from competing international demand.
Those are some of the recommendations we would like to bring forward.